Last edition
News about "lymphoma"
Australia Approves MINJUVI (tafasitamab) for Relapsed or Refractory Follicular Lymphoma
Australia approves MINJUVI (tafasitamab) with rituximab and lenalidomide, the first chemo-free dual-targeted therapy for relapsed follicular lymphoma.
Lymphoma | 24/04/2026 | By News Bureau
AbbVie reported positive Phase III results showing epcoritamab improved progression-free survival versus standard chemoimmunotherapy in relapsed/refractory diffuse large B-cell lymphoma, reinforcing its potential as a CD3xCD20 bispecific therapy.
Lymphoma | 19/01/2026 | By News Bureau | 184
Lupin to Present Phase 1 Data on LNP3693 (STING agonist) at ESMO Congress 2025
Lupin will present data from its Phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, scheduled to be held from October 17 to October 21, 2025.
Lymphoma | 13/10/2025 | By Dineshwori | 298
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy